38,597 Shares in Alto Neuroscience, Inc. $ANRO Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 38,597 shares of the company’s stock, valued at approximately $85,000. Y Intercept Hong Kong Ltd owned approximately 0.14% of Alto Neuroscience at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 146.2% during the first quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock worth $3,456,000 after buying an additional 950,000 shares during the period. Peapod Lane Capital LLC purchased a new position in Alto Neuroscience in the 2nd quarter worth $613,000. AWM Investment Company Inc. raised its stake in Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after acquiring an additional 214,153 shares during the last quarter. Nuveen LLC acquired a new stake in Alto Neuroscience during the 1st quarter worth about $302,000. Finally, SCS Capital Management LLC purchased a new stake in Alto Neuroscience during the 1st quarter valued at about $144,000.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $11.51 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. The stock has a market capitalization of $311.69 million, a price-to-earnings ratio of -4.82 and a beta of 2.81. The firm’s 50 day simple moving average is $6.80 and its 200-day simple moving average is $4.18. Alto Neuroscience, Inc. has a 12 month low of $1.60 and a 12 month high of $15.18.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ANRO. HC Wainwright increased their price objective on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. Chardan Capital began coverage on shares of Alto Neuroscience in a report on Monday, September 29th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Robert W. Baird lifted their price objective on shares of Alto Neuroscience from $10.00 to $16.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.